Overall survival ‐ Gemcitabine plus platinum agent · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus fluoropyrimidine · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes overall response rate compared with vandetanib (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes overall response rate compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes grade 1 ‐ 4 anaemia compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus vandetanib changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes overall response rate compared with S‐1 (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes grade 1 ‐ 4 anaemia compared with S‐1 (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with best supportive care (very low certainty).
1 finding from 1 review